Redeye comments on the new multi-year agreement that Dignitana has signed with Konica Minolta in Jap...
Redeye comments on Modelon's proposed rights issue, which will provide the company with a good cushi...
Redeye provides a research update following the Q1 2024 report from Respiratorius.
We have talked to Lagercrantz's CEO, Jörgen Wigh, and VP Niche Products Divsion, Jonas Ahlberg, abou...
Redeye initiates coverage of Kancera, a Swedish life science company developing candidates targeting...
CEPS miss on one-off tax item Halving hybrid leads to higher CEPS '24e-'26e CEPS CAGR of ~14% vs sec...
Embellence hosted a CMD on 20 May 2024 New financial targets leverage brand strength We raise '24e-'...
Adjusted EBITDA of GBP 1.6m, +29% vs. ABGSCe We raise '24e-'26e EBITDA by 12-20% Share is trading at...
Redeye comments on the outcome of Alzecure’s rights issue, that secured some SEK39m before issue cos...
Should lead to SEK 30-60m order for ClavisterConsensus could lift '26e EBITDA by 8-12%Additional ord...
First Venture Sweden (”First Venture” eller ”Bolaget”) är ett investmentbolag med fokus på snabbväxa...
Redeye comments on CLS’ strategy change with an increased focus on the neurosurgery segment.
CirChem (”CirChem” eller ”Bolaget”) har presenterat Bolagets Q1-rapport och fortsätter på den inslag...
DevPort redovisar det näst bästa kvartalet någonsin.
En investering i Biofrigas Sweden AB (”Biofrigas” eller ”Bolaget”) ger exponering mot den växande ma...
Exel decided on the terms of its rights offering, which should enable strategy implementation after ...
Redeye comments on Maximum Entertainment’s Q1-results which where largely in line with our forecasts...
Mangold uppdaterar sin syn på greentech-bolaget ChargePanel efter det första kvartalet 2024.
Minor estimate changes Solid pace of public procurement wins '24e EV/EBITA ~9x What to expect in Q1...
With Mendus’s Q124 results, management recapped its clinical priorities, which are all progressing a...